Microalbuminuria—A Biomarker of Renal Microvascular Disease

REFERENCES

• de Zeeuw D, Parving HH, Henning RH. Microalbuminuria as an early marker for cardiovascular disease. J Am Soc Nephrol. 2006; 17: 2100–2105
   PubMed Web of Science ®Google Scholar
• Parving HH, Lewis JB, Ravid M, Remuzzi M, Hunsicker LG. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: A global perspective. Kidney Int. 2006; 69: 2057–2063
   PubMed Web of Science ®Google Scholar
• Tapp RJ, Shaw JE, Zimmet PZ, Balkau B, Chadban SJ, Tonkin AM, Welborn TA, Atkins RC. Albuminuria is evident in the early stages of diabetes onset: Results from the Australian Diabetes, Obesity, and Lifestyle Study (Aus–Diab). Am J Kidney Dis. 2004; 44: 792–798
   PubMed Web of Science ®Google Scholar
• Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003; 63: 225–232
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Fussi A, Illieva AP, Bruno S, Illier IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Enelordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G. Bergamo Nephrologic Diabetes Complicaions Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004; 331: 1941–1951
   Google Scholar
• Parving HH, Mogensen CE, Jensen HA, Ervin PE. Increased urinary albumin excretion rate in benign essential hypertension. Lancet. 1974; 1: 1190–1192
   PubMed Web of Science ®Google Scholar
• Atkins RC. The epidemiology of chronic kidney disease. Kidney Int Suppl. 2005; 67: S14–S18
   Google Scholar
• Hillege HL, Janssen WM, Bak AA, Diercks GF, Gubbee DE, Crijns HJ, Van Gilst WH, De Zeeu WD, De Jong PE, PREVEND Study Group. Microalbuminuria is common, also in a nondiabetic, non hypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med. 2001; 249: 519–526
   PubMed Web of Science ®Google Scholar
• Wachtell K, Palmieri V, Olsen MH, Bella JN, Aalto T, Dahlof B, Gerdts E, Wright JT, Jr, Papadermetriou V, Mogensen CE, Borch-Johnsen K, Ibsen H, Devereux RB. Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. Losartan Intervention for Endpoint Reduction. Am Hent J. 2002; 43: 319–326
   Google Scholar
• Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984; 310: 356–360
   PubMed Web of Science ®Google Scholar
• Stchouwer CDA, Smulders YM. Microalbuminuria and risk for cardiovascular disease: Analysis of potential mechanisms. J Am Soc Nephrol. 2006; 17: 2106–2111
   Google Scholar
• Ljungman S, Wikstrand J, Hartford M, Berglund G. Urinary albumin excretion—a predictor of risk of cardiovascular disease: A prospective 10-year follow-up of middle aged nondiabetic normal and hypertensive men. Am J Hypertens. 1996; 9: 770–778
   PubMed Web of Science ®Google Scholar
• Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Jchroll M, Jensen JS. Urinary albumin excretion: An independent predictor of ischemic heart disease. Arteioscler Thromb Vasc Biol. 1999; 19: 1992–1997
   PubMed Web of Science ®Google Scholar
• Nankervis A, Nicholls K, Kilmartin G, Allen P, Ratnaike S, Martin FIR. Effect of perindopril on renal histomorphometry in diabetic subjects with microalbuminuria: A three-year placebo controlled biopsy study. Metabolism 1998; 47(Suppl. 1)12–15
   PubMedGoogle Scholar
• Oagtakybab ME, Miller PL, Jumping-Eagle S, et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997; 99: 342–348
   Google Scholar
• Foretto P, Maner M, Bortoloso E, et al. Glomerular ultrastructure in type 2 diabetes (abstract). J Am Soc Nephrol 1998; 9: 114A
   Google Scholar
• Moriya T, Moriya R, Yajima Y, et al. Urinary albumin as an indicator of diabetic nephropathy lesions in Japanese type 2 diabetic patients. Nephron 2002; 91: 292–299
   Google Scholar
• de Jong PE, Curhan GC. Screening, monitoring, and treatment of albuminuria: Public health perspectives. J Am Soc Nephrol 2006; 17: 2120–2126
   PubMed Web of Science ®Google Scholar
• Futrakul N, Vongthavarawat V, Sirisalipotch S, et al. Tubular dysfunction and hemodynamic alteration in normoalbuminuric type 2 diabetes. Clin Hemorheol Microcirc. 2005; 32: 59–65
   PubMed Web of Science ®Google Scholar
• Futrakul N, Sila-asna M, Futrakul P. Therapeutic strategy towards renal restoration in chronic kidney disease. Asian Biomedicine. 2007; 1: 33–44
   Web of Science ®Google Scholar
• Futrakul P, Yenrudi S, Futrakul N, Sensirivatana R, Kingwatanakul P, Jungthirapanich J, et al. Tubular function and tubulointerstitial disease. Am J Kidney Dis. 1999; 33: 886–891
   PubMed Web of Science ®Google Scholar
• Futrakul N, Butthep P. Early detection of endothelial dysfunction and early therapeutic correction effectively restore renal function in type 2 diabetic nephropathy. Ren Fail. 2005; 27: 493–494
   PubMed Web of Science ®Google Scholar
• Futrakul P, Tosukhowong P, Valyapongpichit Y, Tipprukmas N, Futrakul P, Patumraj S. Oxidative stress and hemodynamic maladjustment in chronic renal disease: A therapeutic implication. Ren Fail. 2002; 24: 433–445
   PubMed Web of Science ®Google Scholar
• Futrakul N, Tosukhowong P, Patumraj S, Siriviriyakul P, Tipprukmas N, Futrakul P. Treatments of hemodynamic maladjustment and oxidative stress prevent renal disease progression in chronically serve glomerulonephritdes. Ren Fail. 2003; 25: 839–844
   PubMed Web of Science ®Google Scholar
• Deekajorndech T. Fractional excretion of magnesium (FE Mg) in systemic lupus erythematosus. J Med Assoc Thai. 2005; 88: 743–745
   Google Scholar
• Deekajorndech T. Biomarker for detecting early tubulointerstitial disease and ischemia in glomerulopathies. Ren Fail. 2007; 29: 1013–1017
   PubMed Web of Science ®Google Scholar
• Futrakul N, Panichakul T, Butthep P, Futrakul P, Jetanalin P, Patumraj S, et al. Ganoderma lucidum suppresses endothelial cell cytotoxicity and proteinuria in persistent proteinuric focal segmental glomerulosclerosis (FSGS) nephrosis. Clin Hemorheol Microcirc. 2004; 31: 267–272
   PubMedGoogle Scholar
• Futrakul N, Butthep P, Patumraj S, Siriviriyakul P, Futrakul P. Microvascular disease and endothelial dysfunction in chronic kidney disease: Therapeutic implication. Clin Hemorheol Microcirc. 2006; 34: 265–271
   Google Scholar
• Futrakul P, Poshyachinda M, Yenrudi S, Salikul P, Sensirivatana R, Futrakul N, et al. Intrarenal hemodynamic abnormality in severe form of glomerulonephritis: Therapeutic benefit with vasodilators. J Med Assoc Thai . 1992; 75: 375–385
   PubMedGoogle Scholar
• Futrakul N, Laohaphaibul A, Futrakul P. Glomerular endothelial dysfunction and hemodynamic maladjustment in severe vesicoureteric reflux. Ren Fail. 2003; 25: 479–483
   PubMed Web of Science ®Google Scholar
• Futrakul N, Futrakul P, Siriviriyakul P. Correction of peritubular capillary flow reduction with vasodilators restores function in focal segmental glomerulosclerotic nephrosis. Clin Hemorheol Microcirc. 2004; 31: 197–205
   PubMed Web of Science ®Google Scholar
• Liang XB, Ma LJ, Naito T, Wang Y, Madaio M, Zent R, Pozzi A, Fogo AB. Angiotensin type 1 receptor blocker restores podocyte potential to promote glomerular endothelial cell growth. J Am Soc Nephrol. 2006; 17: 1886–1895
   PubMedGoogle Scholar
• Satchell SC, Herper SJ, Tooke JE, Kerjaschki D, Saleem MA, Mathieson PW. Human podocytes express angiopoietin 1, a potential regulator of glomerular vascular endothelial growth factor. J Am Soc Nephrol. 2002; 13: 544–550
   PubMed Web of Science ®Google Scholar
• Kriz W, Elger M, Nagata M, Kactzler M, Uiker S, Koeppen-Hageman I, et al. The role of podocytes in the development of glomerulosclerosis. Kidney Int. 1994; 45(Suppl)S64–S72
   Google Scholar
• Rennke HG. How does glomerular epithelial cell injury contribute to progressive glomerular damage?. Kidney Int. 1994; 45(Suppl.)S58–S63
   Google Scholar
• Shulman K, Resen S, Tognazzi K, Manseau EJ, Brown LF. Expression of vascular permeability factor (VPF/VEGF) is altered in many glomerular diseases. J Am Soc Nephrol. 1996; 7: 661–666
   PubMed Web of Science ®Google Scholar
• Futrakul N, Butthep P, Chunhakarn S, Banyatsappasin W. A deficient EGF enhances endothelial cell loss and impaired renal function. Ren Fail. 2006; 28: 449
   PubMed Web of Science ®Google Scholar
• Futrakul N, Yenrudi S, Sensirivatana R, Watana D, Laohaphaibul A, Watanapenphaibul K, et al. Peritubular capillary flow determines tubulointerstitial disease in idiopathic nephrotic syndrome. Ren Fail. 2000; 22: 329–335
   PubMed Web of Science ®Google Scholar
• Futrakul N, Butthep P, Futrakul P. Altered vascular homeostasis in chronic kidney disease. Clin Hemorheol Microcirc. 2008; 38: 201–207
   PubMed Web of Science ®Google Scholar
• Futrakul N, Futrakul P. Renal microvascular disease in aging population: A reversible process?. Ren Fail. 2008; 30: 353–356
   PubMed Web of Science ®Google Scholar
• Verzola D, Gandolfo MT, Ferrario F, Rastoldi MP, Villaggio B, Gieniorio F, et al. Response to renal microvascular and tubular injuries in type II diabetic nephropathy. Kidney Int. 2008; 74: 390–391
   Google Scholar
• Futrakul N, Futrakul P. Renal microvascular and tubular injuries in type II diabetic nephropathy. Kidney Int. 2008; 74: 390
   Google Scholar